8-K: AtriCure Announces Strong Preliminary 2024 Results and Positive Outlook for 2025

AtriCure reported preliminary 2024 financial results showing 17% revenue growth and provided a positive 2025 outlook with projected revenue between $517 million and $527 million.

Summary

• AtriCure announced preliminary unaudited results for the fourth quarter and full year 2024, showing a 17% revenue increase for both periods compared to 2023.
• Fourth quarter revenue is expected to be $124.3 million, with U.S. revenue at $101.6 million and international revenue at $22.7 million.
• Full year 2024 revenue is expected to be $465.3 million.
• The company anticipates full year 2024 adjusted EBITDA between $26 million and $29 million, and an adjusted loss per share between $0.74 and $0.80.
• For 2025, AtriCure projects revenue between $517 million and $527 million and positive adjusted EBITDA between $40 million and $44 million.
• The company also expects modest cash flow generation for the full year 2025.
• AtriCure will host an Analyst & Investor Day on March 26, 2025, to discuss its portfolio, pipeline, and financial goals.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, positive future guidance, and a focus on innovation and market expansion. The company's financial outlook for 2025 is also encouraging.

Positives

• AtriCure experienced strong revenue growth in both the fourth quarter and full year 2024, with a 17% increase in both periods.
• International revenue showed significant growth of 28% in the fourth quarter of 2024.
• The company is projecting continued revenue growth and improved profitability in 2025.
• AtriCure expects to generate positive adjusted EBITDA and modest cash flow in 2025.
• The company is actively expanding its market reach and product portfolio.
• AtriCure is focused on innovation and clinical science to drive growth.

Negatives

• The company is experiencing ongoing pressure in its U.S. Hybrid franchise.
• The company expects an adjusted loss per share of approximately $0.74 to $0.80 for full year 2024.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• There is ongoing pressure in the U.S. Hybrid franchise which may impact future growth.
• The company's financial results are preliminary and unaudited, and may change when audited results are released.

Future Outlook

AtriCure anticipates continued growth in 2025, with projected revenue between $517 million and $527 million, positive adjusted EBITDA between $40 million and $44 million, and modest cash flow generation.

Management Comments

• Michael Carrel, President and Chief Executive Officer of AtriCure, stated that 2024 was another year of remarkable growth and innovation for AtriCure.
• Michael Carrel also mentioned that they expect overall momentum of their business to continue in 2025 despite ongoing pressure in their U.S. Hybrid franchise.
• Michael Carrel said that the team is excited to highlight their leading portfolio of products and innovative pipeline for market expansion at their Analyst and Investor Day.

Industry Context

AtriCure operates in the medical device industry, specifically focusing on treatments for atrial fibrillation and post-operative pain management. The company's growth is driven by the increasing prevalence of Afib and the need for effective surgical solutions. The company is also expanding into pain management, which is a growing market.

Comparison to Industry Standards

• AtriCure's 17% revenue growth in 2024 is strong compared to the overall medical device industry, which typically sees single-digit growth rates.
• Companies like Medtronic and Abbott, which also operate in the cardiac device space, have reported varying growth rates, but AtriCure's focus on surgical ablation and LAA management provides a differentiated market position.
• The projected 2025 revenue growth and positive adjusted EBITDA indicate a positive trajectory compared to some competitors who may be facing challenges in profitability.
• The company's focus on clinical trials and innovation aligns with industry trends towards evidence-based medicine and advanced technologies.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and positive outlook.
• Employees may be motivated by the company's growth and recognition as a top workplace.
• Customers (healthcare providers) will benefit from the company's innovative products and solutions.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• AtriCure will release audited 2024 results and provide a reconciliation of non-GAAP measures to GAAP measures.
• The company will host a conference call in February to discuss the fourth quarter and full year 2024 financial results.
• AtriCure will host an Analyst & Investor Day on March 26, 2025, to discuss its portfolio, pipeline, and financial goals.

Key Dates

Keywords

AtriCure, atrial fibrillation, Afib, revenue, EBITDA, financial results, medical devices, surgical ablation, cryoSPHERE, AtriClip, Hybrid AF Therapy, investor day, pain management, LAA management